Phio Pharmaceuticals Corp (NASDAQ:PHIO) reported a decrease of 28.02% in short interest. It was announced in March by FINRA the 150,500 short interest on PHIO. That’s 28.02% down from 209,100 shares. Former PHIO’s position will need 0 days to recover. It has 343,400 average volume. Phio Pharmaceuticals Corp’s short interest float is 0.96%.

The stock increased 2.21% or $0.008 during the last trading session, hitting $0.37.Phio Pharmaceuticals Corp. has 305,165 shares volume, 10.90% up from normal. PHIO is downtrending and has moved 86.46% since March 10, 2018. The stock underperformed the S&P 500 by 90.83%.

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer.The firm is valued at $6.72 million. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.Currently it has negative earnings. The firm also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity.

For more Phio Pharmaceuticals Corp. (NASDAQ:PHIO) news posted recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “RXi Pharmaceuticals (RXII) Presents At 10th Annual Biotech Showcase 2018 – Slideshow – Seeking Alpha” posted on January 09, 2018, “RXi Pharma up 38% on positive results from study of lead candidate in retinal scarring – Seeking Alpha” on August 01, 2018, “Ionis Pharmaceuticals Is Poised To Disrupt Biotech – Seeking Alpha” with a publish date: January 23, 2018, “RXi Pharmaceuticals: Moving On Promising Scar Treatment – Seeking Alpha” and the last “RXi Pharmaceuticals (RXII) Presents At Ladenburg Thalmann 2017 Healthcare Conference – Slideshow – Seeking Alpha” with publication date: September 27, 2017.